Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China flag China · Delayed Price · Currency is CNY
13.21
-0.19 (-1.42%)
Aug 14, 2025, 2:45 PM CST
-1.42%
Market Cap17.75B
Revenue (ttm)5.28B
Net Income (ttm)648.29M
Shares Out1.47B
EPS (ttm)0.44
PE Ratio29.90
Forward PE22.87
Dividend0.25 (1.87%)
Ex-Dividend DateJul 7, 2025
Volume6,466,920
Average Volume11,613,201
Open12.93
Previous Close13.40
Day's Range12.93 - 13.49
52-Week Range9.01 - 14.34
Beta0.41
RSI59.95
Earnings DateAug 30, 2025

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pan... [Read more]

Sector Healthcare
Founded 1998
Employees 1,926
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002399
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.